Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Plasma volume

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    787 result(s) found for: Plasma volume. Displaying page 4 of 40.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-002125-27 Sponsor Protocol Number: OPZ006 Start Date*: 2013-12-19
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: Phase 1b/2, Multicenter, Open-label Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-001061-32 Sponsor Protocol Number: mRNA-3704-P101 Start Date*: 2019-10-25
    Sponsor Name:ModernaTX, Inc.
    Full Title: A Global, Phase 1/2, Open Label, Dose Escalation Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3704 in Patients with Isolated Methylmalonic Acidemia Due to Methylmalo...
    Medical condition: Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002538-32 Sponsor Protocol Number: MY-1-2015 Start Date*: 2015-10-26
    Sponsor Name:Medicinsk Forskningsafsnit, Regionshospitalet Holstebro (Department of Medical Research, Regional Hospital Holstebro)
    Full Title: THE EFFECT OF ACYL-GHRELIN ON SODIUM REABSORPTION VIA ENAC IN HEALTHY VOLUNTEERS IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER STUDY
    Medical condition: The physiological responses to Acyl-ghrelin-injection on the sodium reabsorption via ENaC in healthy subjects.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003815-71 Sponsor Protocol Number: AK-1-2012 Start Date*: 2013-02-08
    Sponsor Name:Department of Medical Research
    Full Title: The effect of furosemide on fluid volumes and biomarkers in urine for measurement of sodium and water channel activity in healthy subjects
    Medical condition: healthy people
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004848 10049506 Investigation NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005226-21 Sponsor Protocol Number: ARD12181 Start Date*: 2012-03-12
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated with Ruxolitinib and with a Current Diagnosis of Intermediate-2 or High-Risk Primary Myelofibrosis,...
    Medical condition: Hematopoietic neoplasm
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10018864 Haematopoietic neoplasm NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended) AT (Completed) ES (Prematurely Ended) DE (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000978-68 Sponsor Protocol Number: Start Date*: 2006-12-18
    Sponsor Name:AstraZeneca
    Full Title: Treatment of systemic effects in patients with COPD
    Medical condition: Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease state characterized by airflow limitation that is not fully reverible. The airflow limitation is usually progress...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005211-32 Sponsor Protocol Number: DS1040-B-U107 Start Date*: 2017-03-08
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Single Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of DS-1040b when Added to ...
    Medical condition: DS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including Pulmonary Embolism (PE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037379 Pulmonary embolism and thrombosis HLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002523-36 Sponsor Protocol Number: UP0100 Start Date*: 2022-07-13
    Sponsor Name:UCB Biopharma SRL
    Full Title: A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, TOLERABILITY, AND SAFETY OF A SINGLE DOSE OF STACCATO ALPRAZOLAM IN ADOLESCENT STUDY PARTICIPANTS WITH EPILEPSY
    Medical condition: Treatment of stereotypical prolonged seizure
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-002963-92 Sponsor Protocol Number: CLRX712A12201 Start Date*: 2020-02-05
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, placebo-controlled, subject and investigator blinded study investigating the safety, tolerability and preliminary efficacy of 8-week treatment with intra-articular LRX712 to regenerat...
    Medical condition: Cartilage injuries
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031161 Osteoarthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006677-83 Sponsor Protocol Number: HuLuc63-1703 Start Date*: 2010-04-26
    Sponsor Name:AbbVie Biotherapeutics Inc. (AbbVie)
    Full Title: A Phase 1b/II, Multicenter, Open-Label, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination with Lenalidomide and Dexamethasone in Subjects with Relapse...
    Medical condition: Patients with relapsed multiple myeloma (MM).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002538-19 Sponsor Protocol Number: SCIENCEII-Pilot Start Date*: 2019-01-10
    Sponsor Name:Rigshospitalet
    Full Title: Stem Cell therapy in non-IschEmic Non-treatable dilated CardiomyopathiEs II: a pilot study
    Medical condition: The overall aim of the project is to test the feasibility and safety of allogeneic adipose-derived stromal cells (CSCC_ASC) investigational medicinal product, to improve myocardial function in pati...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003774-17 Sponsor Protocol Number: 483-001 Start Date*: 2008-08-01
    Sponsor Name:Vantia Ltd
    Full Title: A double-blind, placebo-controlled dose response study to investigate pharmacodynamics and pharmacokinetics of single and repeated oral doses of VA106483 in elderly male subjects
    Medical condition: Nocturia.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029446 Nocturia LLT
    Population Age: Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002511-26 Sponsor Protocol Number: 08062019 Start Date*: 2019-12-20
    Sponsor Name:Rigshospitalet
    Full Title: Repeated Injection Therapy of Allogeneic Stem Cells in Ischemic No-option Patients - A Multi-Centre Study (SCIENCE REPEAT)
    Medical condition: Ischemic heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019285 Heart failure, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003331-32 Sponsor Protocol Number: AZI003 Start Date*: 2013-06-18
    Sponsor Name:KULeuven and University Hospitals Leuven
    Full Title: A PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF PRE-TRANSPLANT AND PROMPT POST-TRANSPLANT TREATMENT WITH AZITHROMYCIN TO IMPROVE EARLY ALLOGRAFT FUNCTION AND OUTCOME AFTER LUNG TRANSPLANTA...
    Medical condition: EARLY LUNG ALLOGRAFT FUNCTION AND OUTCOME AFTER LUNG TRANSPLANTATION
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10050437 Prophylaxis against heart and lung transplant rejection LLT
    14.1 10022891 - Investigations 10016547 FEV LLT
    14.1 10042613 - Surgical and medical procedures 10050433 Prophylaxis against lung transplant rejection LLT
    14.1 10022891 - Investigations 10006414 Bronchial biopsy abnormal LLT
    14.1 10022891 - Investigations 10025041 Lung biopsy abnormal LLT
    14.1 10022891 - Investigations 10016549 FEV 1 abnormal LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10049202 Bronchiolitis obliterans LLT
    14.1 10042613 - Surgical and medical procedures 10025127 Lung transplant PT
    14.1 10021428 - Immune system disorders 10049237 Acute cellular rejection LLT
    14.1 10021428 - Immune system disorders 10066543 Acute allograft rejection LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039008 Reversible airways obstruction NOS LLT
    14.1 10021428 - Immune system disorders 10019319 Heart-lung transplant rejection PT
    14.1 10022891 - Investigations 10016550 FEV 1 decreased LLT
    14.1 10022891 - Investigations 10057799 Computerised tomogram thorax abnormal PT
    14.1 10022891 - Investigations 10063078 Bronchoalveolar lavage abnormal PT
    14.1 10042613 - Surgical and medical procedures 10056409 Heart and lung transplant PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10068956 Respiratory tract inflammation PT
    14.1 100000004862 10049083 Respiratory tract infection NOS LLT
    14.1 10022891 - Investigations 10016553 FEV 1 low LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001137-16 Sponsor Protocol Number: LPC-003 Start Date*: 2011-04-20
    Sponsor Name:LIDDS AB
    Full Title: An open, single dose, antitumor effect study of 2-hydroxyflutamide as a controlled release product (Liproca® Depot), injected into the prostate in patients with localized prostate cancer.
    Medical condition: Localized prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Prematurely Ended) FI (Completed)
    Trial results: View results
    EudraCT Number: 2013-002312-27 Sponsor Protocol Number: 13-031 Start Date*: 2013-08-14
    Sponsor Name:Zealand Pharma
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess Clinical Efficacy and Safety of Danegaptide in Patients with ST-Elevation Myocardial Infarction undergoing Primary Per...
    Medical condition: The treatment of acute myocardial infarction, AMI is aimed at enabling the return of blood flow to the ischemic myocardium, thereby limiting the size of the infarct. However the reperfusion by itse...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10047065 - Vascular disorders 10063837 Reperfusion injury PT
    16.1 100000004849 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-000259-28 Sponsor Protocol Number: 54179060LYM3003 Start Date*: Information not available in EudraCT
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma.
    Medical condition: Mature B-Cell Neoplasm
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) BE (Completed) CZ (Completed) HU (Completed) DE (Completed) NL (Completed) ES (Completed) PL (Completed) BG (Completed) Outside EU/EEA SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001598-25 Sponsor Protocol Number: IG1002 Start Date*: 2011-10-25
    Sponsor Name:INSTITUTO GRIFOLS, S.A.
    Full Title: A multicenter, randomized, controlled study to evaluate the efficacy and safety of short-term plasma exchange followed by long-term plasmaphereses with infusion of human albumin combined with intra...
    Medical condition: Mild to Moderate Alzheimer's Disease patients.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-002268-28 Sponsor Protocol Number: ULA04 Start Date*: 2020-03-10
    Sponsor Name:Department of Hepatology and Gastroenterology, Aarhus University Hospital
    Full Title: Single-center, randomized, double-blind, placebo-controlled clinical trial for the safety, tolerability and efficacy of ularitide in cirrhosis patients with refractory ascites.
    Medical condition: Liver cirrhosis with refractory ascites.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024667 Liver cirrhosis LLT
    20.0 10017947 - Gastrointestinal disorders 10003445 Ascites PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005886-15 Sponsor Protocol Number: VASOCONTROL-I Start Date*: 2021-07-21
    Sponsor Name:University Medical Center Groningen
    Full Title: Evaluation of pharmacokinetic and –dynamic characteristics of norepinephrine for the augmentation of arterial blood pressure in healthy volunteers prior to and during general anesthesia
    Medical condition: Bloodpressure during anaesthesia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 10 08:02:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA